CPM
REGN icon

Connective Portfolio Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Connective Portfolio Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-630
Closed -$449K – 55
2024
Q4 		$449K Sell
630
-25,000
-98% -$21M 0.67% 51
2024
Q3 		$2.77M Buy
25,630
+25,000
+3,968% +$27.8M 4.9% 5
2024
Q2 		$662K Hold
630
– – 1.08% 37
2024
Q1 		$606K Hold
630
– – 1.07% 39
2023
Q4 		$553K Hold
630
– – 1.13% 33
2023
Q3 		$518K Hold
630
– – 1.58% 29
2023
Q2 		$453K Sell
630
-45
-7% -$34.7K 1.12% 39
2023
Q1 		$555K Sell
675
-1,900
-74% -$1.43M 1.76% 25
2022
Q4 		$1.86M Buy
2,575
+500
+24% +$369K 3.96% 4
2022
Q3 		$1.49M Buy
2,075
+725
+54% +$456K 4.76% 5
2022
Q2 		$798K Buy
1,350
+675
+100% +$439K 1.37% 31
2022
Q1 		$471K Hold
675
– – 1.01% 35
2021
Q4 		$426K Buy
+675
New +$415K 0.75% 43

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Connective Portfolio Management's REGN Position: Q1 2025 in Review

Connective Portfolio Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 630 shares — an estimated $449K sold.

Connective Portfolio Management first reported a position in REGN in Q4 2021 and held it in 13 quarters. The position peaked at $2.77M in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Connective Portfolio Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Connective Portfolio Management sold 630 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $449K.
  • Connective Portfolio Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 13 quarters.
  • Connective Portfolio Management's Regeneron Pharmaceuticals position peaked at $2.77M in Q3 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Connective Portfolio Management's 13F filing for Q1 2025, filed 22 Apr 2025.